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Abstract 
Objective: Postoperative pain is a common complaint after surgery. Although pain is 
a subjective experience, there is now emerging evidence to suggest that hereditary 
influence may also play an important role in postoperative pain. The purpose of this 
study is to identify the contribution of 11 single nucleotide polymorphisms (SNPs) to 
pain after major intra-abdominal surgery. 
Methods: We studied a total of 267 patients undergoing open abdominal surgery. 
Postoperative pain relief was provided by patient controlled analgesia (PCA) machine 
for the first 72 hours after surgery. In the daily interview，patients rated the pain 
intensity, frequency and severity of opioid related side effects. The number of PCA 
demand and daily morphine consumption were also recorded. We contacted the 
patients again at 6 months after surgery for occurrence, pain intensity and 
characteristics of persistent pain after surgery. Univariate and multivariate regression 
models were build to detect factors and covariates that contributed to postoperative 
pain and morphine consumption. The associations between SNPs or haplotype with 
acute and chronic postoperative pain were tested by analysis of variance and 
multivariate regression, as appropriate. 
Results: In patients using PCA morphine for postoperative analgesia, daily morphine 
consumption and number of PCA demands were significantly higher in patients 
carrying the G allele for A118G polymorphism in the opioid receptor (OPRMl) gene 
{P = 0.02). Opioid related side effects were also diminished in these patients. Pain 
scores were however similar to the wild type. Other SNPs have no effect on pain 
III 
response or morphine requirement during the first three days after surgery. At six 
months follow-up, we observed a lower rate of chronic postoperative pain in patients 
carrying minor allele for GTP cyclohydrolase (GCHl), Catechol-O-methyl transferase 
(COMTl) and parrestin2 genes. This protective effect remained significant for SNPs 
and their haplotypes in GCHl gene among patients who reported severe pain (pain 
score > 5). 
Conclusions: Pain responses after surgery are altered by genetic mutations. Our 
analysis demonstrated that A118G polymorphism in OPRMl gene reduced the [i 
opioid receptor sensitivity. Patients carrying the minor allele required larger doses of 
morphine to achieve the same degree of analgesia. We also showed that a haplotype in 
GCHl gene, and polymorphisms in the COMTl and Parrestin2 genes reduced the 
incidence of chronic postoperative pain. Preoperative identification of genetic 















的次數CP = 0.02)。阿片相關副作用也在這類病人身上較少發生。不過他們的疼痛 
評分與野生型病人相近。其他SNPs不影響術後頭三日內的疼痛反應或是嗎啡需 
求。在六月後的隨訪中’我們觀察到在攜帶GTP cyclohydrolase ( GCH1 )， 
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Chapter 1. Review of postoperative pain 
Postoperative pain is a common complaint after surgery. In a study of 5,703 
ambulatory surgical patients, 30% of patients (1,495/5,703) had moderate to severe 
pain with pain score > 5 in an 11 -point self-assessing verbal scale (McGrath et al, 
2004). Another study of 250 adults having surgical procedures showed that 
approximately 80% of patients experienced acute pain after surgery. Of these patients, 
86% had moderate, severe, or extreme pain, with more patients experiencing pain 
after discharge home. Experiencing postoperative pain was indicated the most 
common concern (59%) among patients in this study (Apfelbaum et al, 2003). 
Similarly, in a large survey of 10,811 patients undergoing all types of procedures, at 
least 24% had inadequate pain relief during the first few postoperative days, and this 
was strongly associated with patient dissatisfaction [adjusted odds ratio (95% 
confidence intervals) = 3.94 (3.16-4.91), P < 0.0005] (Myles et al, 2000). 
Moreover, a substantial proportion of patients continue to suffer pain for months 
to years after their initial procedures, even though the wound has apparently healed. 
In this regard, up to 38% of patients reported severe pain [visual analogue scale > 5 
(out of 10)] for at least three months duration which has developed after surgery 
where other causes such as disease recurrence or a pre-existing pain syndrome have 
been excluded (Table 1.1.) (Classification of chronic pain. 1986; Macintyre et al., 
2010; Toth et al., 2009). These patients have chronic physical disability and are under 
1 
significant psychosocial distress (Kehlet et al” 2006; Poleshuck and Green, 2008). 
Chronic pain receives a global concern and more knowledge about the long term 
sufferings is also required by local clinicians in Hong Kong. 
It is well known that acute postoperative pain exaggerates inflammatory 
responses, protein catabolism, lipolysis, and glucose intolerance. This is associated 
with hyperalgesia, allodynia, fluid and sodium retention, increased sympathetic 
discharges, hypercoagulation and immuosuppression (Liu and Wu, 2009; Carli and 
Schricker, 2009). Similarly, persistent pain after surgery incurs significant loss of 
productivity, medical expenses, and hospital admissions. The development of chronic 
postoperative pain should be considered as a greater loss to individuals who may have 
gone through an otherwise successful and curative surgery. 
Although pain, as a subjective experience, is influenced by local culture, current 
mood status and prior perception, there is emerging evidence to suggest that 
hereditary influence may also play an important role in postoperative pain. In animal 
studies, it is reported that genetic contribution accounted for 28-76% of the variability 
in response to noxious stimuli and analgesic treatment (Mogil, 1999). 
Currently, over 3,000 single nucleotide polymorphisms (SNPs) in 317 genes are 
linked to the biological pathways that may influence pain sensitivity and/or 
2 
psychological state associated with pain# (LaCroix-Fralish et aL, 2007). Unfortunately, 
majority of the data are derived from transgenic animal models, and there are only 
few human studies. Given the broad biological functions of these SNPs, it is plausible 
that patients who carry the variant genes would have different response to pain after 
surgery. Therefore, additional genetic information may enable clinicians to identify 
the susceptible individual who may present excessive postoperative pain and to 
optimize treatment to relief acute and long term sufferings. 
The purpose of this study was to identify the genetic contribution of postoperative 
pain perception after major abdominal surgery. In this observational cohort study, we 
tested the association between 11 candidate SNPs with acute postoperative pain and 
the development of chronic pain at 6 months after surgery. 
林 Pain Genes Database. Available at http://www.ibldesign.com/imogil/PainGenedb content.html. 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 2. Candidate Genes 
2.1 II Opioid Receptor Gene 
Opioids, such as morphine, are commonly prescribed for the treatment of 
moderate-to-severe pain after surgery. Intuitively, genetic variation of the opioid 
receptor may have profound effect on patient's response to both endogenous and 
exogenous opioid administration. In this regard, a single nucleotide substitution, 
A118G (rs 1799971), in the opioid receptor gene \i\ (OPRMl) gene has received 
most attention. Specifically, a substitution at nucleotide position 118 (with respect 
to the initiator codon) results in a change in amino acid residue (from asparagine 
to aspartic acid) at position 40 from the N-terminus of the p. opioid receptor. This 
is associated with a loss of extracellular sites for N-glycosylation. In an ex vivo 
study, Bond and co-workers demonstrated a 3-fold increase in (3 endorphin 
binding and activity in G allelic receptors (Bond et al, 1998). However, clinical 
data are more variable. Table 2.1 summarizes the effect of G allele on the doses of 
morphine required to treat a variety of pain conditions. A number of studies 
reported no difference in the morphine requirement between subjects with the G 
allele and the wild type. However, these data are limited because the allelic 
frequency was less than 10% in Caucasians. Therefore, the studies did not have 
adequate power to detect a clinically important difference in opioid requirement. 
Several studies have attempted to overcome this problem by evaluating the 
Asian population, of whom the expected allelic frequency is approaching 50%. In 
6 
a cohort of 588 Singaporean women undergoing cesarean section with intrathecal 
morphine and bupivacaine administration, the average dose of morphine used in 
the G allelic patients, during the first 24 hours after surgery, was more than that in 
the wide type. But postoperative pain was modest < 3 (out of 10), and may have 
limited the effect size of the study (Sia et ai, 2008). Interestingly, a similar study, 
recently presented as an abstract, did not detect a difference in postoperative 
morphine analgesia among the G allele patients (Wong et al, 2008). Moreover, 
the current available evidence of the clinical relevance of this SNP did not 
withhold a meta-analysis. (Walter and Lotsch, 2009) 
In summary, few studies have indicated a change in functional activity of the 
G allelic opioid receptor, this may reduce opioid efficacy but an appropriately 
designed study is required to confirm the clinical effect. Our study with large 
sample size and a Chinese cohort who would be undergoing major surgery may 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.2 ATP-binding cassette B1 (ABCBl) / multiple drug resistance 1 (MDRl) gene 
This gene encodes the expression an efflux transporter, P-glycoprotein, in the 
brain. It is responsible for the active transport of opioids (endogenous or 
exogenous) out from the brain into the circulation. In rats, downregulation of 
P-glycoprotein expression was associated with enhanced analgesia (King et ah, 
2001; Xie et al, 1999). In this regard, genetic polymorphism C3435T (rsl045642) 
leads to ineffective efflux transport and may increase the bioavailablity of opioid. 
In patients with cancer pain, carriers of T allele had better analgesia compared 
with the wild type. It is therefore plausible that the same polymorphism will affect 
morphine analgesia in the perioperative setting. 
2.3 Catechol-O-methyltransferase (COMT) gene 
COMT is one of the two enzymes that metabolize dopamine, which is an 
important neurotransmitter in the pain pathway. A functional SNP of the COMT 
gene (rs4680) results in the substitution of valine by methionine at amino acid 
position 158, and has been shown to decrease enzyme activity. In healthy 
volunteers, the substitution was associated with an over-activity of dopaminergic 
pathways and a depletion of neuronal enkaphalin. This is ‘ followed by an 
upregulation of opioid receptors (Zubieta et al, 2003). In this regard, individual 
with met/met genotype are more likely to develop tempromandibular joint pain 
syndrome. Therefore the association between COMT polymorphism and 
10 
perioperative pain is of considerable interest in postoperative pain. 
2.4 PArrestin2 gene 
PArrestin2 is an intracellular protein that inhibits guanine nucleotide binding 
protein (G protein) coupled receptor (GPCR), such as the \x opioid receptor 
(Conner and Christie, 1999; Keith et al., 1998). In knockout models, morphine 
analgesia was enhanced and prolonged in mice when |3Arrestin2 gene was deleted 
(Bohn et al., 2003; Bohn et al, 2002). Recent studies have identified a gene 
polymorphism, T8622C (rsl 045280) that may affect the function of the protein. In 
patients receiving morphine for the treatment of cancer pain, inadequate analgesia 
was associated with patients with T allele. The effect of pArrestin2 polymorphism 
on perioperative pain and the development of chronic postoperative pain remained 
to be explored. 
2.5 Transient receptor potential (TRP) gene 
The transient receptor potential (TRP) channels are a family of loosely related 
ionotropic channels that are activated by heat, cold, pain and osmolarity (Chang et 
al, 2010; Dong et al, 2010). TRP subfamily A member 1 (TRPAl), also known as 
ankyrin-like protein with transmembrane domains 1 (ANKTMl), is activated by 
cold (Story et al, 2003)，whereas TRPVl, also known as vanilloid receptor 
ionophore 1 (VRl), respond to warmth and heat. Point mutations have been 
identified in TRPAl (rsl 1988795) and TRPVl genes (rs8065080) and may affect 
11 
the sensitivity of nociceptors. Animal studies have shown that this may be 
involved in the development of chronic pain. Nonetheless, there is a lack of 
systematic study to evaluate the functional consequences of these genetic 
variations. 
2.6 GTP cyclohydrolase 1 (GCHl)gene 
GTP cyclohydrolase (GCH) is the rate limiting enzyme for tetrahydrobioterin 
(BH4) synthesis (Thony et al., 2000). Since BH4 is an important cofactor in the 
synthesis of phenylalaine, tyrosine and other biogenic amines, downregulation of 
GCH activity results in a depletion of neurotransmitter in the pain pathways. 
Therefore, inhibition of BH4 production was associated with attenuated 
inflammatory response and pain hypersensitivity. A protective haplotype of 5 
SNPs in the GCHl gene has been shown to produce a lower rate of chronic low 
back pain after lumbar discectomy (Tegeder et al., 2006), experimental capsaicin 
pain (Tegeder et al, 2008; Campbell et al, 2009) and delay cancer pain therapy 
(Lotsch et al., 2010). However, other studies have been unable to confirm these 
findings (Kim and Dionne, 2007). 
General information of candidate genes is summarized in Table 2.2.. In summary, 
a number of genetic polymorphisms may affect the pharmacodynamics (OPRMl, 
PArrestin2) and pharmacokinetics (ABCBl/MDRl) of morphine. This may affect the 
quality of analgesia during the early postoperative period. There are also genes that 
12 
regulate neurotransmission in the pain pathways (COMT, GCHl, TRPAl, TRPVl). 
Intuitively, variations in these genes may enhance (or suppress) the nociceptive 













































































































































































































































































































































































































































































































































































































Chapter 3. Hypothesis and Experimental Design 
3.1 Hypothesis 
In this study, we hypothesized that patients with candidate genetic 
polymorphisms are associated with altered response to morphine analgesia during the 
early postoperative period. We also hypothesized that the genetic polymorphisms can 
affect rates of chronic postoperative pain, 6 months after surgery. 
3.2 Objectives 
The specific objectives of this study were: 
(1) to determine the association between polymorphisms in the candidate gene loci 
with postoperative pain score, morphine requirement and opioid related side 
effects in patients undergoing major abdominal surgery 
(2) to determine the incidence chronic postoperative pain that has arisen and persisted 
from major abdominal surgery, performed 6 months ago; 
(3) to determine the association between polymorphisms in the candidate gene loci 
with the risk of chronic postoperative pain. 
3.3 Experimental Design 
The present study was a prospective observational cohort study to evaluate the 
association between genetic polymorphisms and pain in the early postoperative period 
and 6 months later after major abdominal surgery. 
15 
We chose to study patients undergoing open abdominal surgery, because these 
patients generally require a substantial amount of opioid after surgery. This should 
therefore maximize the potential difference in pain score, morphine consumption and 
possible opioid related side effects. 
3.4 Role in this study 
I participated in the study design. In the experimental part, I extracted DNA from 
most of the patients and participated in the genotyping. I also performed all statistical 
analysis. 
16 
Chapter 4. Methods 
The Joint Chinese University of Hong Kong — New Territories East Cluster 
Clinical Research Ethics Committee approved this study (reference no.: CRE 
2008.285). Written informed consent was obtained from all patients. 
4.1 Patients 
Patients were eligible for the study if they were aged between 18 and 80 years, 
undergoing major open abdominal surgery and were deemed to be able to use the 
patient controlled analgesia (PCA) machine with intravenous morphine for 
postoperative pain relief. Patients were excluded if they had pre-existing chronic pain 
syndrome and had received opioid therapy for more than two weeks prior to surgery. 
Patients were also excluded if they were allergic to morphine, and had a history of 
significant liver or renal disease. Patients who were planned to receive neuraxial or 
regional techniques for perioperative analgesia were not included in the study. 
4.2 Anesthetic procedure 
All patients received sevoflurane based anesthesia. Propofol 1-2.5 mg/kg IVI was 
given for induction of anesthesia. Perioperative analgesia was provided by morphine 
0.05-0.15 mg/kg IVI and muscle relaxation was facilitated by rocuronium 0.5 mg/kg 
IVI. The lungs were ventilated via tracheal tube using air-oxygen mixture to achieve 
an end-tidal carbon dioxide tension between 35 and 45 mmHg. Anesthesia was 
17 
maintained with sevoflurane at 0.7-1.2 minimum alveolar concentration (MAC). The 
MAC value was adjusted for age and gender. Administration of intravenous fluid was 
determined by the attending anesthetists. At the end of surgery, neuromuscular block 
was reversed by neostigmine 40 jig/kg and atropine 20 (ig/kg in all patients. Regional 
block was not used. 
4.3 Postoperative management 
Postoperative pain relief was provided by PCA machine for the first 72 hours after 
surgery. The PCA was programmed to deliver morphine IVI at 20-40 |Lig/kg demand 
bolus and 10 min lockout intervals. During the study period, all patients were 
encouraged to use PCA morphine alone. In patients who requested to discontinue the 
PCA machine, oral analgesics such as diclofenac, paracetamol were prescribed. 
Although we controlled much of the perioperative management, this reflected 
day-to-day anesthetic practice in the local hospitals. 
All patients were registered as a study participant and were appropriately 
de-identified. Data was collected before and at 24 hours intervals for a period of 72 
hours following their surgery. 
In patients who returned to the operating theatre for further surgery or who had 
switched to oral analgesics within the three postoperative days, we retained all data 
collected until the time of event for the final analysis. 
18 
Standard education materials were provided to both patients and nursing staffs. 
Patient characteristics, pre-existing major medical conditions and details on the 
surgical procedure were obtained before anesthesia. Five milliliter of whole blood was 
taken before surgery and was stored for subsequent laboratory analysis. After surgery, 
patients were interviewed daily by experienced research staff. During the interview, 
we recorded pain intensity according to a visual analogue scale (VAS) (Myles et al., 
1999; Aun et aL, 1986), the frequency and severity of any opioid related side effects. 
The number of PCA demand and daily morphine consumption were also collected. 
4.4 Patient follow-up 
All patients were contacted at 6 months after surgery, by face to face interview 
and telephone interview. During the interview, patients were asked to rate the intensity 
and characteristics of pain using a 11 -point visual analogue scale，according to the 
IMMPACT recommendations (Dworkin et al, 2005; Turk et al, 2006; Wang et al., 
1996). In patients who reported persistent pain after surgery, additional imaging and 
biomarker measurements were ordered to exclude disease recurrence according to our 
local practice. 
4.5 Definition of endpoints 
4.5.1 Acute pain and opioid related side effects 
4.5.1.1 Pain scores at rest, with deep breathing and after coughing were recorded at 24 
19 
hours, 48 hours, and 72 hours after surgery. A pain score of 0 implied no pain 
and 10 was the most severe pain imagined. 
4.5.1.2 Morphine consumption and the number of PCA demands were collected at 24 
hours intervals during the first three postoperative days. 
4.5.1.3 Opioid related side effects were assessed daily with an Opioid Related 
Symptom Distress Scale (Gan et al, 2004) . Patients were asked to report the 
frequency, severity and the extent of distress for ten possible side effects of 
opioid and this included fatigue, drowsiness, nausea, dizziness, inability to 
concentrate, constipation, difficulty in urination, pruritus, confusion and 
vomiting. 
The frequency of the side effects except vomiting was recorded using a 
5-point likert scale (0-4): 0 = none, 1 = rare, 2 = sporadic, 3 = often, 4 = 
always. The actual number of emetic episodes was recorded. 
The severity of symptom was scored as 0 = none, 1 = slight, 2 = moderate, 3 = 
severe, 4 = very severe. 
The distress score was rated using a 6-point scale (0-5): 0 = no side effects, 1 
=no t bothered for the side effects at all, 2 = a little bit, 3 = somewhat, 4 = 
quite a bit, 5 = very much. 
4.5.2 Chronic postoperative pain 
4.5.2.1 Any persistent pain was pain score > 0 that had risen and persisted for > 3 
months after surgery that was not due to disease recurrence or pre-existing 
20 
pain syndrome. 
4.5.2.2 Severe persistent pain were pain score > 5，lasting for > 3 months during the 
first 12 months after surgery. 
4.5.2.3 The proportion of patients seeking pain related treatment for chronic 
postoperative pain. 
The patients, attending anesthesiologists and the research assistants were blinded 
to the genotype. 
21 
Chapter 5. Genotyping 
Buffy coat was prepared from patients' whole blood by centrifuging at 3,000 rpm 
for 10 minutes in Labofuge 400R machine (Heraeus Limited, Germany). Genomic 
DNA of each patient was extracted from 200 |uL buffy coat using QIAamp DNA 
blood mini kit 250 (Qiagen，Valencia, CA). Extraction process was performed 
according to the manufacturer's recommendation, with an approximate yield of 3-10 
|Lig. We used the Nanodrop 1000 (Thermo Fisher Scientific, MA) to confirm the 
quality and quantity of DNA extracted. Genotyping was performed using Taqman 
SNP genotyping assays and Taqman genotyping master mix (Applied Biosystem， 
Foster City, CA). Information about the SNPs and corresponding assays is shown in 
Table 5.1. The polymerase chain reaction (PGR) analysis was performed using 
384-well optical plates. Each well had a volume of 5 [iL containing 10 ng genomic 
DNA, 2.5 |LIL Taqman genotyping master mix and 0.25 |iL 20x probes and primers. 
The machine used for SNP discrimination was a 7900HT Fast Real-Time PCA System 
(Applied Biosystem, Foster City, CA). The software for pre-read, post-read and 
standard curve was Sequence Detection Systems version 2.3. The default 

































































































































































































































































































































































































































































































































































































































































































































































































Chapter 6 Statistical Analysis and Sample Size 
6.1 Statistical analysis 
The Hardy-Weinberg equilibrium analysis was performed for observed genotypes 
and the % test value was used to determine whether there was a significant deviation 
from this equilibrium. A haplotype is a combination of alleles at different loci on the 
same chromosome and D' and r are the usual statistics to compare the strength of 
linkage disequilibrium (LD) between pairs of markers. D' is calculated by dividing 
the population genetic parameter D (see below, Tajima, 1989) by its maximum 
possible value, adjusting for the allelic frequencies of the pair of SNPs (Sklar, 2005). 
The D' value varies from 0 to 1. When D’ = 1, it indicates no evidence of an historical 
recombination event occurring between the two SNPs, i.e. complete LD. In the 
contrary, D' = 0 indicates an absence of LD. r is calculated by dividing D by the 
product of the four allele frequencies at the two SNPs. In this case / = 1 indicates 
perfect LD. It occurs when only two haplotypes are observed because the SNPs have 
the same allele frequency. Intermediate values of r^ indicate how well one SNP 
predicts the behavior of the second SNP (Sklar, 2005). When 0.8, the SNP can be 
regarded as highly correlated to another. 
We performed haplotype analysis using the Haploview (version 4.2). Haploblocks 
were generated and D' and r^ were calculated. These measures were based on the 
pairwise disequilibrium coefficient, D, which is the difference between the probability 
of having two alleles on the same haplotype if they are independent in the population. 
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A value of 0 implies independence, while 1 means complete co-transfer. 
Differences in patient characteristics and surgical details features were tested 
using 兄2 or analysis of variance (ANOVA) as appropriate. Pain scores at rest, during 
deep breathing and after coughing, as well as daily morphine consumption, number of 
PCA demands were compared among groups of different genotypes, for the three 
postoperative days, using ANOVA with repeated measures. 
Univariate and multivariate regression models were generated to detect factors 
and covariates that contributed to postoperative pain and postoperative morphine 
consumption . Covariates included other SNPs, age, gender and education level. 
We tested the difference in opioid related side effects among different genotypes 
using ANOVA with repeated measures. The average score for each symptom was the 
mean of the patient-reported scores in each of the three dimensions (frequency, 
severity and distress). The overall composite side effect score for each day was the 
average of all 10 individual symptom score. We also calculated the 
dimension-specific composite scores (for frequency, severity and distress) as the mean 
score of all symptoms in each dimension. 
The difference in the rates of chronic postoperative pain (pain score > 0) and 
severe chronic pain (pain score > 5) among different genotypes and haplotypes were 
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analyzed using ^ test. Pain scores were compared among groups using ANOVA. A 
multivariate logistic regression model was used to test the predictors that may affect 
the risk of chronic postoperative pain. Covariates included genotypic, haplotypic, 
patient characteristics and surgical details. All statistical analyses were performed 
using SPSS 15.0 (Chicago, IL US). A significant result was defined by a P value less 
than 0.05. 
6.2 Sample size 
We estimated the sample size based on the power analysis to detect an association 
between polymorphisms and chronic pain. This is because the % analysis would 
require the largest number of patients. Figure 6.1 shows a large scale simulation for 
the estimation of statistical power using the "Power for Association With Error" 
(PAWE) software (Gordon et al., 2002; Edward et al, 2005). 
For any SNP/haplotype with a frequency > 25%, a sample size of 250 patients 
would have > 80% power to detect such association when the incidence of chronic 
postoperative pain was greater than 5% 
In the acute pain study, smaller sample size is required. By using G*Power 3.1.2 
(Universitat Kiel, Germany), we have calculated that 159 patients would be sufficient 
to detect a difference in pain score by 25% (one-way ANOVA; df = 2). 
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Figure 6.1. Statistical power to detect an association between varying frequency of single nucleotide 
polymorphisms and chronic postoperative pain. 
0 5 
* Incidence of 
0 5 ' ' ^ ^ ^ ' ^ . y ^ O . O B chronic post-
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Chapter 7. Demographic, genotype and haplotype result 
7.1 Patient characteristics 
Between February, 2009 and October, 2009, a total of 267 patients 
undergoing open intra-abdominal surgery entered the study. Table 7.1 summarizes 
patient characteristics and surgical details in the entire cohort of patients. We recorded 
the use of nitrous oxide because a previous study has demonstrated better pain relief 
in the early postoperative period after intraoperative nitrous oxide administration. 
(Stiglitz et al, 2010) 
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Table 7.1. Patient Characteristics and Surgical Details. 
Demographic information Values 
Female 175 (65.5%) 
Age 54.4 ± 11.2 
Height (cm) 157 士 19 
Weight (kg) 59.3 ± 1 3 
BMI (kg/m^) 22.8 士 5.6 
Education level (0/1/2/3)* 45/121/57/40 
Pre-existing major medical conditions 
Liver disease 71 (37.5%) 
Respiratory disease 12 (4.5%) 
Kidney disease 6 (2.2%) 
Diabetes mellitus 39 (14.6%) 
Current smoker 19(7.1%) 
Anti-epileptic medication 3 (1.1%) 
Antidepressant use 4(1.5%) 
Alcohol abuse 3 (1.1%) 
Surgical wound 
Infra-umbilical 172 (64.4%) 
Both infra- and supra-umbilical 86 (32.2%) 
Horizontal 125 (46.8%) 
Wound longer than 10 cm 204 (76.4%) 
Surgical details 
Duration of surgery (min) 202 士 118 
Total intraoperative dose of morphine (mg) 14.1 士 25.7 
Use of nitrous oxide 116 (43.4%) 
Vales are number (%) or mean ± standard deviation.*0 = never went to school, 1 二 completed school to 
age of 12 years, 2 = completed school to age of 18 years, 3 = completed school past age of 18 years. 
29 
7.2 Genotypes and haplotypes 
Genotyping was completed in all patients. A total of 11 SNPs were included in this 
study, all of them had a measured minor allele frequency > 10% (range: 11-44%) and 
a P value > 0.05 in Hardy-Weinberg equilibrium test (Table 7.2). The detected allele 
frequency was similar to the reported data in Chinese population while it was deviated 
from that of CEU population (Utah residents with Northern and Western European 
ancestry from the CEPH collection) (Table 7.3). 
We evaluated five SNPs in GCHl gene that have been shown to affect pain 
sensitivity in previous study (Tegeder et al., 2006). Haploview was used to define four 
haploblocks (Figure 7.1). Blocks 1 and 2 were defined by using the confidence 
interval approach in Haploview. Block 4 was defined using solid spine of LD in 
Haploview. Since the SNP rs8007201 was highly correlated with two other SNPs in 
Block 1，rs752688, rs4411417 and rs8007201 were manually combined to form a 
haploblock. The definitions of the four haploblocks are shown in Figure 7.1 and the 
frequency of haplotypes in each haploblock is listed in Table 7.3. 
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Table 7.2. Genotype and allele distribution. 
Genotypic frequency (%) Allelic frequency (%) 
Identity of SNPs* Homozygous Homozygous Wild-type 
Heterozygous Minor allele 
wild type minor allele allele 
OPRMl gene 
rs 1799971 [A/G] 40.4 44.9 14.6 62.9 37.1 
ABCBl /MDRl gene 
rs 1045642 [C/T] 36.7 49.4 13.9 61.4 38.6 
COMTl gene 
rs4680 [G/A] 57.3 33.7 9.0 74.2 25.8 
PaiTestin2 gene 
rs 1045280 [T/C] 62.5 31.5 6.0 78.3 21.7 
GCH1 gene 
rs8007201 [A/G] 38.6 43.1 13.9 62.9 37.1 
rs752688 [C/T] 39.7 46.1 12.7 63.7 36.3 
rs3783641 [T/A] 77.9 14.5 1.1 89.0 11.0 
rs4411417 [T/C] 40.8 45.7 12.4 64.4 35.6 
rs8007267 [C/T] 74.5 21.3 1.5 87.5 12.5 
TRPVl 
rs8065080 [C/T] 32.6 50.2 15.7 58.6 41.4 
TRPAl 
rs 11988795 [C/T] ^ ^ ^ ^ 44.0 
* S N P = single nucleot ide po lymorph ism. S N P alleles are in brackets , where [Al le le i=Wild 
type/Allele2=variant SNP] . 
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Table 7.3. Allele frequency (%) in our study cohort and HapMap database*. 
Present study CHB# CEU$ 
Identity of SNPs* Wild-type Minor Wild-type Minor Wild-type Minor 
allele allele allele allele allele allele 
OPRMl gene 
rs 1799971 [A/G] 62.9 37.1 63.9 36.1 84.5 15.5 
ABCBl/MDRl gene 
rs 1045642 [C/T] 61.4 38.6 62.6 37.4 42.9 57.1 
COMTl gene 
rs4680 [G/A] 74.2 25.8 71.2 28.8 52.2 47.8 
parrestin2 gene 
rs 1045280 [T/C] 78.3 21.7 83.3 16.7 68.1 31.9 
GCHl gene 
rs8007201 [A/G] 62.9 37.1 60.7 39.3 59.7 40.3 
rs752688 [C/T] 63.7 36.3 58.9 41.1 78.9 21.1 
rs3783641 [T/A] 89.0 11.0 83.3 16.7 7.50 2.50 
rs4411417 [T/C] 64.4 35.6 58.9 41.1 78.9 21.1 
rs8007267 [C/T] 87.5 12.5 8.50 1.50 7.50 2.50 
TRPVl 
rs8065080 [C/T] 58.6 41.4 56.6 43.4 35.8 64.2 
TRPAl 
rs 11988795 [CAT] 56.0 ^ ^ ^ ^ 13.9 
* H a p M a p D a t a Re l 28 Phase l l+I I I , A u g u s t 10，on N C B I B 3 6 assembly, d b S N P b l 2 6 
# H a n C h i n e s e in Be i j ing , China . $ U tah res idents wi th Nor the rn and Western E u r o p e a n ances t ry 
f r o m the C E P H col lec t ion . 
Al le l ic f r e q u e n c y fo r r s l 1988795 w a s obta ined f r o m P u b M e d . 
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Figure 7.1. Haploview analysis ofCGHl gene. 
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The red boxes indicate the levels of linkage disequilibrium (LD) between two single 
nucleotide polymorphisms, numbers in black are the D, values, while the numbers in 
white are the r^ values. 
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Table 7.4. Frequency of four haploblocks. 




















Chapter 8. Acute postoperative pain 
Figures 8.1.-8.4 show the changes in pain score, at rest, during deep breathing 
and after coughing in patients with different genotypes. Pain score decreased 
significantly with time (P < 0.001). However, the SNPs A118G in OPRMl gene, 
rs4680 in COMTl gene and rsl045280 in pArrestin2 gene did not affect pain score. 
In contrast, patients who were homozygous TT in ABCBl/MDRl gene had a 
significantly lower pain score compared with other genotypes on the first 
postoperative day {P = 0.04). This difference was however small (mean difference = 
1.1) (95% C.L 0.26 - 1.91) and was largely disappeared in a multivariate analysis that 
include other SNPs, age, gender and education level as covariates (Table 8.1). 
We performed a multivariate regression considering the effects of the type of 
surgical wound, age gender and the education level. Genotypes were also included in 
this test (wild type versus variant carriers). The percentage of variance explained in 
the regression model was increased by 2.4 fold (2.7 to 6.7%) when genetic factors 
were included. Although higher education level was associated with lower pain score 
(P = 0.02), this was not affected by any factor tested in the analysis that included 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 9. Morphine consumption for early postoperative pain 
Figures 9.1 - 9.2 show the daily doses of morphine during the first three days 
after surgery. There was no difference in morphine consumption and the number of 
PCA demands among patients carrying different genotypes. Patients who were 
homozygous met/met in SNP rs4680 of the COMTl gene received significantly less 
morphine during the first day after surgery (P = 0.03), but the difference was small 
and quickly disappeared after the first postoperative day (P = 0.07). 
9.1 Patients using alternative analgesia 
In this study, we noted that a large number of patients (n = 142, 53%) requested 
non-opioid analgesics during the first 3 postoperative days. This usually included 
non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol. There were 30 
patients in the second day and 64 patients on the third day, who discontinued the 
administration of PCA morphine. The characteristics of patients who requested 
non-opioid analgesics and/or early discontinuation of the PCA pump are summarized 
in Table 9.1. Interestingly, there were more patients carrying the G allele of A118G 
SNP in the OPRMl gene (14.5%) who request non-opioid analgesics than those with 
the wild type (6.5%) (P = 0.04). 
9.2 Result in the patients using morphine alone 
Since the opioid-sparing effect of NSAIDs may confound the results in this study, 
we evaluated a subgroup of patients (n = 125) who received PCA morphine alone for 
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postoperative analgesia during the first three days after surgery. In this analysis, pain 
scores were similar among patients with different genotypes. However, daily 
morphine consumption was significantly higher in patients with G allele for A118G 
polymorphism in the OPRMl gene, compared with the wild type, Figure 9.2 (P = 
0.02). The number of PCA demands in carriers of G allele, 40 士 29, was also higher 
than the wild type, 34 士 30, P = 0.03. Morphine consumptions and PCA demands 
were not affected by polymorphisms in ABCBl/MDRl and Parrestin2 genes. The 
daily morphine consumption and PCA requirement are summarized in Appendix 1. 
Using a multivariate model, we were able to demonstrated that weight (尸=0.01), 
male patients (P < 0.02) and long procedures {P < 0.01) were associated with 
increased morphine consumption in the whole cohort. The total percentage of 
variance explained was increased from 12 to 15.4% when genetic factors were 
considered in the regression model. The association of weight and morphine 
consumption was also supported by the multivariate model in patients receiving 
morphine alone (Table 9.2). 
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Table 9.1. Characteristics of Patients using PCA morphine and non-opioid analgesia. 
All patients Patients receiving PCA Patients using 
morphine alone non-opioid analgesia 
Demographic information 
No. of patients 267 142 125 
Female 175 (65.5%) 89(62.7%) 86(68 .8%) 
Age 54.4 ± 11.2 55.8 ±10.7 52.9 ±11.7 
Height (cm) 157 士 19 159.0 士 16.3 156.6 士21.5 
Weight (kg) 59.3 ± 13 60.0 士 13.8 58.5 ±12.0 
BMI (kg/m^) 22.8 ± 5 . 6 23.1 ±5.1 22.4 士6.1 
Education level (0/1/2/3)* 45/121/57/40 23/66/26/23 22/55/31/17 
Pre-existing major medical conditions 
Liver disease 71(37.5%) 46 (32.4%) 25 (20.0%) 
Respiratory disease 12 (4.5%) 5(3 .5%) 1 (5.6%) 
Kidney disease 6 (2.2%) 4 (2.8%) 2 (1 .6%) 
Diabetes mellitus 39(14 .6%) 24(16.9%) 15(12.0%) 
Current smoker 19(7.1%) 13(9.2%) 5 (4.0%) 
Anti-epileptic medication 3 (1 .1%) 2(1 .4%) 1(0.8%) 
Antidepressant use 4 (1 .5%) 2(1 .4%) 2 (1 .6%) 
Alcohol abuse 3 (1 .1%) 2(1 .4%) 1(0.8%) 
Surgical wound 
Infra-umbilical 172 (64.4%) 82 (57.7%) 90 (72.0%) 
Both infra- and supra-umbilical 86 (32.2%) 41(28.9%) 45 (36.0%) 
Horizontal 125 (46.8%) 74(52.1%) 51(40 .8%) 
Wound longer than 10 cm 204 (76.4%) 113 (79.6%) 91 (72.8%) 
Surgical details 
Duration of surgery (min) 202 ± 1 1 8 210.4 ±121.3 192.4 ±113.1 
Total intraoperative dose of morphine (mg) 14.1 士 25.7 11.1 ±20.8 17.4士30.1 















































































































































































































































































































































































































































































































































































































































































































































Figure 9.1. Daily morphine consumption in all patients for four candidate single 
nucleotide polymoiphisms. The points were mean value, error bars were standard 
errors. 
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Figure 9.2. Daily morphine consumption in patients receiving morphine alone for 
four candidate single nucleotide polymorphisms. The points were mean value, error 
bars were standard errors. 
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Chapter 10. Opioid-related Side Effects 
Table 10.1 shows the side effects related to opioid administration. Patients 
carrying the G allele of the A118G SNP in the OPRMl gene had lower incidence of 
side effects, and less disturbed by the symptoms compared with the wild type. 
There were also minor effects of SNPs in other genes on opioid related symptoms. 
The changes were modest and transient. Details are listed in Appendix II and III. 
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Table 10.1. Opioid related Symptom Distress Scale Score in Patients with Different 
A118G Genotype in the OPRMl gene. 
Genotype 
AA ^ GG 
No. of patients 108 120 39 
Individual symptoms 
Fatigue 1.3 士 0.8 1.3 ±0 .9 1.0 ±0 .8 
Drowsiness 1.1 士 0.8 1.1 ±0 .8 0.9 土 0.7 
Inability to concentrate 0.3 士 0.5 0.3 士 0.7 0.2 ± 0.4* 
Nausea 0.8 ±0 .7 0.7 ± 0.7 0.4 ±0.6** 
Dizziness 1.0 士 0.8 0.8 士 0.8 0.6 士 0.7* 
Const ipat ion 0.1 ± 0 . 3 0.1 ± 0.2 0.1 ± 0.3 
Itchiness 0.5 士 0.7 0.4 士 0.6 0.2 ± 0.4 
Difficulty passing urine 0.0 土 0.2 0.1 ±0.3 0.0 ± 0.2 
Confusion 0.1 士 0.4 0.1 土 0.3 0.1 ±0 .2 
Retching/vomiting 0.3 ± 0.5 0.2 ±0.5 0.3 ± 0.4 
Composite symptom distress scale score 
Frequency-specific score 0.7 士 0.4 0.7 士 0.4 0.5 ±0.4** 
Severity-specific score 0.6 士 0.3 0.5 士 0.4 0.4 ±0.3** 
Distress-specific score 0.5 士 0.4 0.5 土 0.4 0.3 ±0.3** 
Overall score 0.6 ±0 .4 0.6 士 0.4 0.4 ±0.3** 
Values are presented as mean 士 standard deviations. */** Significant difference between variant 
homozygotes (GG) and the other two groups (* denotes P value < 0.05 and **P value < 0.01). 
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Chapter 11. Chronic postoperative pain 
11.1 Patient characteristics 
Patient follow-up occurred between 3rd 2009 and June 2010. The median 
follow-up time was 6.1 (range: 6 - 7.5) months. Follow-up questionnaires were not 
completed in 39 patients. 13 patients (4.8%) had died during the follow-up period. 
Two patients (0.7%) were uncontactable and 24 patients were undergoing cancer 
therapy and too weak to participate further. Follow-up data were therefore available 
from 228 (85%) of the study patients. 
A total of 91 patients (39.9%) reported persistent wound pain after surgery. 
Reports were adjudicated by pain physicians and were deemed unrelated to disease 
recurrence and other pre-existing pain syndrome. Among these patients, 20 (8.8%) 
had pain score > 5 (10 = worst possible pain). Characteristics of wound pain are listed 
in Table 11.1. 
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Table 11.1. Descriptions of Wound Pain 6 Months After Surgery. 
Pain characteristics Values 
Total number of patients reviewed 228 
Wound pain in the last four weeks 91 (39.9%) 
Worst pain score in the past two weeks* 1.3 士 2.1 
Pruritus around the wound 38 (16.7%) 
Taking regular analgesics for wound pain 21 (9.2%) 
Hospital admission or clinic attendance for pain management 13 (5.7%) 
Felt disabled by wound pain 8 (3.5%) 
Values are number (%) or *mean 士 standard deviation. 
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11.2 Association of genetic polymorphisms and Chronic postoperative pain 
A lower rate of chronic postoperative pain was noted in patients carrying minor 
allele for SNPs in GCHl, COMTl and paiTestin2 genes (Table 11.2). This protective 
effect remained significant for SNPs in GCHl gene in patients who reported severe 
pain (pain score > 5). Using the predefined haploblocks in the GCHl gene, we found 
that patients carrying one copy of C—T in block 1 {P = 0.012), one copy of C_T_A in 
block 3 (尸=0.027) and one copy of C_T_A_T一C (P = 0.022) in block 4 have a lower 
incidence of chronic pain. The pain score was also lower in these patients (Table 


























































































































































































































































































































































































































































































































































































































































































































































Table 11.3. Chronic Pain Score for Different Haplotypes. 
Number of copies of Number of Chronic pain 
the most frequent patients score 
haplotype 
Block 1 
2 9 4 1.6±2.：2 
1 104 0.9 士 1.7* 
0 3 0 1.9 ± 2 . 4 
Block 2 
2 171 1.4 士 2.1 
1 5 2 1.1 士 2.0 
0 4 0.0 
Block 3 
2 8 7 1.6 士 2.2 
1 107 0.9 士 1.8* 
0 3 4 1.8 ± 2 . 4 
Block 4 
2 85 1.7 ± 2 . 2 
1 108 0.9 士 1.7* 
0 ^ 1.7 士 2.3 
*P<0.05 ,ANOVA 
* Significant difference between patients carrying one copy of the haplotype and the other two groups 
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Chapter 12. Discussion 
12.1 Acute postoperative pain 
In this study, we identified a number of genetic polymorphisms that undermined 
the analgesic efficacy of morphine. In this regard, patients carrying G allele for the 
A118G polymorphism in the OPRMl gene were more likely to switch to non-opioid 
analgesics after surgery. In those who continued with patient controlled morphine 
administration, the daily consumption was higher. The incidence and severity of 
opioid related side effects were also reduced. These findings suggested that there 
was a downregulation of \i opioid receptor with OPRMl gene polymorphism, so that 
a larger doses of morphine are required to achieve the same degree of postoperative 
analgesia. 
Our data are in contrast to Bond's work where binding of endogenous opioid 
with G allelic receptors is three times more tightly than the common allelic form 
(Bond et al., 1998). However, using specific allelic expression assay, recent study in 
transfected Chinese hamster ovary cells expressing the G variant receptor reported a 
1.5 fold decrease in mRNA and 10 fold decrease in receptor protein expression 
(Zhang et al” 2005). Similarly, a decrease in cell-surface receptor binding was 
observed in cell lines (HEK293 and AVI2) expressing the G allelic |LI opioid receptor. 
There was also a corresponding impairment in cAMP signaling following agonist 
binding (Kroslak et al., 2007). Finally, in a transgenic mouse model, animals 
harboring the minor allele demonstrated a significant reduction of receptor protein. 
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More importantly, symptoms related to morphine-mediated antinociception and 
naloxone-precipitated morphine withdrawal in these animals were diminished 
(Mague et al., 2009). These findings indicate a loss of receptor function with single 
amino acid substitution, resulting in a decrease in the potency of morphine and its 
active metabolite, moiphine-6-glucuonide, with G allelic \i opioid receptor. 
In human experiments, the potency for morphine to produce pupillary 
constriction was reduced by 51.6-77.3% in healthy individuals carrying at least one 
rare allele (Lotsch and Geisslinger, 2006; Romberg et al., 2005). Although analgesic 
response was diminished, the respiratory depressant effect was not necessary 
reduced to the same extent. Therefore, it is still uncertain as to the overall effect of 
the polymorphism on the in vivo function of the receptor. 
Clinical data are more confusing. A number of reports have failed to 
demonstrate a change in morphine consumption for postoperative analgesia. Others 
have shown a modest increase in the doses of morphine required in patients carrying 
the G allele compared with common allele (Klepstad et al., 2004; Ross et al., 2005; 
Fillingim et al., 2005; Janicki et al., 2006; Chou et al, 2006; Chou et al., 2006a; 
Coulbault et al., 2006; Reyes-Gibby et al., 2007; Sia et al., 2008; Wong et al., 2008; 
Campa et al., 2008). These data were limited because the incidence of the minor 
allele was low, and the surgery was minor. Therefore, the sample size was generally 
inadequate to detect a small difference in morphine requirement. We have therefore 
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evaluated a cohort of patients undergoing major laparotomy, for whom morphine 
consumption is substantial after surgery, and the incidence of minor allele is known 
to be high. 
Our data challenge the common belief that postoperative opioid requirement in 
Chinese is less than that in Caucasians. Since a large proportion of the Chinese 
population carries the G allele in the OPRMl gene, it is not surprising that many 
would consider morphine as an ineffective agent and opt for a switch to other 
non-opioid analgesics (Lee et al, 1997; Strezler and Wade, 1981; Camie and Perks, 
1984; Aim et al., 1988; Houghton et al, 1992; Houghton, 1993). 
There are other proteins that may affect n opioid receptor function. parrestin2 is 
known to desensitize and interfere with post-receptor signaling (Conner and Christie, 
1999； Keith et al, 1998). We were unable to detect changes in pain score, morphine 
consumption and opioid related side effects with polymorphism in Parrestin2 gene 
(T8622C, rsl045280). However, it should be clear that the reported SNPs (including 
rsl045280) (Ross et al., 2005) do not produce amino acid substitution and the 
mechanism to affect pain perception remains unclear. 
Polymorphism in ABCBl/MDRl gene (T3435C, rsl045642), however may 
change the pharmacokinetics of morphine. By reducing efflux of the drug from the 
central nervous system, there is an increase in the bioavailability of morphine in the 
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effect site. In this study, we did not observe consistent changes in pain score, 
morphine consumption, however, there was a small increase in nausea score. This 
finding is consistent with a previous study in 74 Caucasians undergoing colorectal 
surgery. A diplotype including the C allele of T3435C SNP increased the rate of 
vomiting and the use of antiemetics, however pain score and analgesic consumption 
were not affected (Coulbault et al., 2006). 
12.2 Chronic postoperative pain 
Ninty-one patients (39.9%) in our cohort reported persistent pain after surgery. 
Among these patients 20 (22.1%) reported severe pain (pain score > 5), and required 
regular analgesics. Many of these patients had hospital admission or clinic 
attendance for pain management within the 6 months after surgery. More importantly, 
a substantial portion of these patients reported significant limitation of their daily 
activities. These data are similar to those reported in previous studies (Table 1.1) 
(Macintyre et al., 2010; Kehlet et al., 2006; Macrae, 2008), indicating a significant 
long term health issue with pain control after surgery. 
While there are other factors predicting chronic postoperative pain, we observed 
a number of genetic polymorphisms that modified the risk. In our study, we 
identified several haploblocks in GCHl gene that reduced the risk of chronic 
postoperative pain. Using bioinformatics tools, four haploblocks in the gene were 
identified. The composition of these haploblocks was slightly different from 
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previous reports (Tegeder et al., 2006; Kim and Dionne, 2007; Tegeder et al., 2008; 
Lotsch et al., 2010), because of different genotypic and haplotypic distribution in our 
cohort of patients. 
The regulation of pain pathway with GCHl gene was first reported in 2006 
(Tegeder et al). In their original study, recurrence of lumbar radiculopathy was 
decreased in patients carrying the protective haplotype. Subsequent reports have 
confirmed the benefits of the haplotype in experimental pain models (Tegeder et al, 
2008; Campbell et aL, 2009) using thermal, electrical, mechanical and chemical 
stimuli. Nevertheless, a recent report failed to demonstrate an association between 
the haplotype and pain response after surgical removal of impacted third molars 
GCHl haplotype reduces BH4 synthesis. Considering BH4 as an essential 
cofactor for nitric oxide production, a downregulation of its production would be 
expected to limit axonal injury and inflammatory pain response in the sensory 
neurons. There are SNPs in other genes that may interfere with nitric oxide 
functioning. Among the large TRP family, TRPVl and TRPAl regulate the 
expression of transient receptor potential channels in 97% of all nociceptors. By 
downregulation of TRPVl and TRPAl expression in the afferent nerve terminals, the 
release of nitric oxide dependent nociceptive mediators is reduced. However, in the 
present study, we were unable to detect an association between TRP genes and 
development of chronic postoperative pain. 
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We also showed that the risk of chronic postoperative pain is reduced in patients 
carrying the minor alleles of COMTl and Parrestin2 gene. Both SNPs affect the pain 
pathway through an indirect mechanism. Polymorphism in COMTl gene increases 
the sensitivity of opioid receptor as a compensatory response to chronic 
dopaminergic inhibition. Mutation with Parrestin2 amplifies post-receptor signaling 
following opioid agonist stimulation. In both cases, endogenous opioid may produce 
larger analgesic effect and prevent the development of chronic postoperative pain. 
Our study is however limited by a limited sample size and short period of 
follow-up. In this study, we found that the non-carriers of the major haplotype in 
Block 2 reported no chronic pain at all but there were only patients in this group. 
Also, when we evaluated the patients who used PCA morphine alone, the number of 
these patients may not be adequate to detect the originally proposed difference. 
Therefore, though there were a number of encouraging positive results, an 
appropriately-designed large cohort study is required to confirm the findings. Also, 
we would choose the cohort of patients undergoing different surgery. This would 
extend our findings in different types of post-surgical patients. 
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Chapter 13. Conclusion 
In summary, our study showed that in patients undergoing major abdominal 
surgery, the analgesic effect of morphine, and the risk of developing chronic 
postoperative pain are affected by genetic polymorphisms. Our analysis 
demonstrated that A118G polymorphism reduced the opioid receptor sensitivity. 
Patients carrying the minor allele required larger doses of morphine to achieve the 
same degree of analgesia. Opioid related side effects are also diminished in these 
patients. There are also a haplotype in GCHl gene, and other polymorphisms in the 
COMTl and (3arrestin2 genes that reduced the incidence of chronic postoperative 
pain. 
Although the data are encouraging, further large cohort studies are required to 
confirm these findings. We also need detailed experiments to explain the functional 
changes in the variants. 
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Appendix IL Opioid Related Symptom Distress Scale Score on Day 
1 and Overall Score Over Time in Patients with Different Genotypes 
Table 5. Opioid Related Symptom Distress Scale Score on Day 1 and Overall Score 
in Patients with Different A118G Genotype in the OPRMl Gene. 
A A ( " = 1 0 8 ) AG (^7= 120) GG {n = 
Side effect scores in the first day 
Fatigue 2.0 士 1.1* 1.9 士 1.1* 1.5 士 1.1* 
Drowsiness 1.9士 1.1* l.Vvl.l* 1.3 ±1.1* 
Inability to concentrate 0.6 士 1.0 0.5 士 0.9 0.3 ± 0.7 
Nausea 1.2±1.1** 1.1 士 1.1** 0.6士 0.9** 
Dizziness 1.5 士 1.1** 1.3 土 1.1** 0.8 土 0.9** 
Constipation 0.1 土 0.6 0.1 土 0.4 0.0 土 0.0 
Itchiness 0.5 ± 0.9 0.5 ± 0.8 0.4 ±0.7 
Difficulty with urination 0.1 ± 0.4 0.1 士 0.7 0.0 士 0.0 
Confusion 0.2 ± 0.7 0.2 ±0.6 0.2 ±0.7 
Retching/vomiting 0.4 士 0.9 0.4 土 0.9 0.4 士 0.8 
Frequency-specific scores l . l ± 0.6** 1.0 ± 0.6** 0.8 ± 0.6** 
Severity-specific scores 0.9 土 0.5** 0.8 土 0.5** 0.5 士 0.4** 
Distress-specific scores 0.8 土 0.6* 0.7 土 0.5* 0.5 士 0.4* 
Overall side effect scores over three days 
Day] 0.9 土 0.5** 0.8 士 0.5** 0.5 土 0.4** 
Day2 0.5 士 0.4 0.4 土 0.4 0.4 土 0.6 
Day3 0.3 ±0.3 0.2 ±0.3 0.2 ±0.3 
Values are mean 士 standard deviations; value < 0.05; **尸 value < 0.01 (ANOVA). 
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Table 6. Opioid Related Symptom Distress Scale Score on Day 1 and Overall Score 
in Patients with Different C3435T Genotype in the ABCBl/MDRl Gene. 
“ CC (77 = 98) CT(/7= 132) T T ( " = 37) 
Side effect scores in the first day 
Fatigue 1.8 土 U 2.0 士 1.1 1.7 士 1.2 
Drowsiness 1.7 士 1.1 1.8 ±1.1 1.4 士 1.3 
Inability to concentrate 0.4 土 0.8 0.6 土 1.0 0.5 土 0.9 
Nausea 0.9 士 1.0** 1.3 士 1.1** 0.6 士 0.9** 
Dizziness 1.2 士 1.1 1.4vl.2 1.2 土 1.2 
Constipation 0.1 士 0.4 0.1 ±0.5 0.1 ±0.3 
Itchiness 0.4 土 0.8 0.5 土 0.8 0.4 ±0.8 
Difficulty with urination 0.1 士 0.6 0.1 士 0.4 0.1 ± 0.5 
Confusion 0.2 ±0.6 0.2 ±0.7 0.2 ±0.7 
Retching/vomiting 0.3 ±0.7 0.5 ±1.0 0.4 士 1.1 
Frequency-specific scores 1.0 ± 0.6* 1.1± 0.6* 0.9 ± 0.7* 
Severity-specific scores 0.7 士 0.5 0.9 士 0.5 0.7 士 0.6 
Distress-specific scores 0.7 ±0.5* 0.8 士 0.6* 0.6 ±0.5* 
Overall side effect scores over three days 
Dayl 0.7 土 0.4 0.9 士 0.5 0.7 土 0.5 
Day2 0.4 士 0.5 0.5 土 0.4 0.4 ±0.5 
Day3 0.之士 0.：3 0.：3 士 0.3 0二土 0.：3 
Values are mean 土 standard deviations; value < 0.05; **P value < 0.01 (ANOVA). 
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Table 7. Opioid related Symptom Distress Scale Score on Day 1 and Overall Score 
in Patients with Different rs4680 Genotype in the COMTl gene. 
GG (77 = 153) AG {n = 90) AA {n = 24) 
Side effect scores in the first day 
Fatigue 1.8 ±1.1 2.1 士 1.1 1.5 土 1.2 
Drowsiness 1.6± 1.1* 2.0 士 1.1* 1.6 士 1.2* 
Inability to concentrate 0.6 ± 1.0 0.4 士 0.8 0.5 士 0.8 
Nausea 1.1 士 1.1 1.0 士 1.0 1.0 土 1.1 
Dizziness 1.3 ± 1.2 1.3 ± 1.1 1.2 土 1.0 
Constipation 0.1 士 0.4 0.1 士 0.4 0.2 士 0.6) 
Itchiness 0.5 土 0.9 0.5 士 0.7 0.3 士 0.7 
Difficulty with urination 0.1 ±0.4 0.1 ± 0.6 0.2 ± 0.7 
Confusion 0.3 ± 0.7 0.2 ±0.6 0.1 ±0.3 
Retching/vomiting 0.5 士 1.0 0.4 土 0.9 0.3 土 0.7 
Frequency-specific scores 1.0 士 0.6 1 • 1 士 0.5 0.9 士 0.6 
Severity-specific scores 0.8 士 0.6 0.8 士 0.5 0.7 士 0.5 
Distress-specific scores 0.7 士 0.6 0.7 土 0.6 0.6 土 0.5 
Overall side effect scores over three days 
Dayl 0.8 士 0.5 0.8 ±0.5 0.7 ±0.5 
Day2 0.5 士 0.5 0.斗士 0.4 0.；3 士 0.：3 
Day3 0.：3 士 0.3* 0.2 士 0.3* 0.1 士 0.3* 
Values are mean 士 standard deviations; value < 0.05 (ANOVA). 
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Table 8. Opioid related Symptom Distress Scale Score on Day 1 and Overall Score 
in Patients with Different Al l 8G Genotype in the OPRMl gene. 
一 TT (77= 167) CT (n = 84) CC (/?= 16) 
Side effect scores in the first day 
Fatigue 1.9 士 U 1.8 ±1.2 2.2 ±0.9 
Drowsiness 1.7 士 1.1 1.6 士 1.2 1.9 ±1.0 
Inability to concentrate 0.5 士 0.9 0.5 士 0.9 0.6 ± 1.0 
Nausea 1.1 士 1.1 1.0 士 1.1 1.2 士 0.8 
Dizziness 1.：3 土 1.1 1.3 ±1.2 1.7 ±0 .8 
Constipation 0.1 土 0.4 0.1 士 0.5 0.0 士 0.0 
Itchiness 0.4 ±0.8 0.5 士 0.9 0.6 士 0.7 
Difficulty with urination 0.1 ±0.5 0.1 土 0.5 0.0 土 0.0 
Confusion 0.2 ±0.6 0.3 ±0.8 0.2 ±0.6 
Retching/vomiting 0.4 士 0.9 0.5 士 0.9 0.4 土 0.9 
Frequency-specific scores 1.0 士 0.6 1.0 士 0.6 1.2 ±0.4 
Severity-specific scores 0.8 土 0.5 0.8 士 0.6 0.9 ± 0.4 
Distress-specific scores 0.7 士 0.5 0.7 士 0.6 0.8 士 0.5 
Overall side effect scores over three days 
Dayl 0.8 士 0.5 0.8 ± 0.5 0.9 ± 0.4 
Day2 0.4 士 0.4 0.4 士 0.4 0.7 ± 0.6 
Day3 0.2 士 0.3 0.2 ±0.3 0.4 土 0.4 
Values are mean 士 standard deviations. 
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Appendix III. Overall Opioid Related Symptoms Distress Scale 
Score in Patients with Different Genotypes. 
Table 9. Opioid related Symptom Distress Scale Score in Patients with Different 
C3435T Genotype in the ABCBl/MDRl gene. 
Genotype 
^ CT TT 
No. of patients 98 132 37 
Individual symptoms 
Fatigue 1.3 士 0.9 1.3 ± 0 . 8 1.2 士 0.8 
Drowsiness 1.1 士 0.8 1.1 士 0.8 0.9 士 0.7 
Inability to concentrate 0.3 土 0.6 0.4 士 0.6 0.3 士 0.5 
Nausea 0.6 土 0.7 0.8 士 0.8 0.5 土 0.5 
Dizziness 0.8 土 0.8 0.9 士 0.8 0.7 士 0.7 
Constipation 0.1 ± 0 . 2 0.1 士 0.3 0.1 士 0.3 
Itchiness 0.4 士 0.7 0.4 士 0.6 0.4 士 0.6 
Difficulty passing urine 0.0 士 0.2 0.1 士 0.2 0.1 士 0.3 
Confusion 0.1 士 0.4 0.1 士 0.：3 0.1 士 0.2 
Retching/vomiting 0.2 士 0.5 0.3 士 0.5 0.2 ± 0.5 
Composite symptom distress scale score 
Frequency-specific score 0.7 士 0.5 0.7 土 0.4 0.6 士 0.4 
Severity-specific score 0.5 士 0.4 0.5 士 0.4 0.5 士 0.3 
Distress-specific score 0.5 ± 0.4 0.5 土 0.3 0.4 士 0.3 
Overall score 0.5 ± 0.4 0.6 ± 0.4 0.5 ± 0.3 
Values are presented as mean 士 standard deviations. 
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Table 10. Opioid related Symptom Distress Scale Score in Patients with Different 
rs4680 Genotype in the COMTl gene. 
Genotype 
GG ^ AA 
No. of patients 153 90 24 
Individual symptoms 
Fatigue 1.3 ± 0 . 8 1.3 土 0.8 0.9 ± 0 . 7 
Drowsiness 1.1 土 0.8 1.2 士 0.8 0.9 土 0.7 
Inability to concentrate 0.4 士 0.6 0.3 士 0.5 0.2 土 0.4 
Nausea 0.8 ± 0.7 0.7 ± 0 . 7 0.5 ± 0.5 
Dizziness 0.9 土 0.8 0.7 士 0.7 0.7 ± 0.7 
Constipation 0.1 士 0.3 0.0 土 0.2 0.1 士 0.2 
Itchiness 0.5 ± 0 . 6 0.4 ± 0 . 6 0.3 ± 0 . 6 
Difficulty passing urine 0.0 士 0.2 0.1 士 0.2 0.1 士 0.3 
Confusion 0.1 土 0.4 0.1 ± 0 . 3 0.0 土 0.1 
Retching/vomiting 0.3 ± 0.6 0.2 士 0.5 0.1 土 0.3 
Composite symptom distress scale score 
Frequency-specific score 0.7 土 0.4 0.7 土 0.4 0.5 土 0.3 
Severity-specific score 0.5 土 0.4 0.5 士 0.3 0.4 士 0.2 
Distress-specific score 0.5 士 0.4 0.5 ± 0.3 0.4 士 0.3 
Overall score 0.6 ± 0.4 0.5 土 0.3 0.4 士 0.3 
Values are presented as mean 士 standard deviations. 
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Table 11. Opioid related Symptom Distress Scale Score in Patients with Different 
rsl045280 Genotype in the paiTestin2 gene. 
Genotype 
TT CT CC 
No. of patients 167 84 16 
Individual symptoms 
Fatigue 1.3 土 0.8 1.2 士 0.8 1.7 士 0.9 
Drowsiness 1.1 士 0.8 1.1 士 0/7 1.4 士 1.0 
Inability to concentrate 0.3 土 0.6 0.3 土 0.5 0.5 土 0.8 
Nausea 0/7 土 0.7 0.7 ±0.7 1.1 土 0.8 
Dizziness 0.8 士 0.8 士 0.8** 1.3 士 0/7** 
Constipation 0.1 士 0.3 0.1 土 0.2 0.0 土 0.0 
Itchiness 0.4 ±0.6 0.4 士 0.7 0.6 士 0.6 
Difficulty passing urine 0.1 土 0.2 0.1 士 0.2 0.0 土 0.0 
Confusion 0.1 土 0.3 0.1 士 0.3 0.2 士 0.7 
Retching/vomiting 0.2 土 0.5 0.3 士 0.5 0.3 土 0.6 
Composite symptom distress scale score 
Frequency-specific score 0.7 士 0.4* 0.6 士 0.4* 1.0 ± 0.5* 
Severity-specific score 0.5 士 0.3 0.5 士 0.4 0.7 土 0.4 
Distress-specific score 0.5 士 0.3 0.5 士 0.4 0.7 土 0.5 
Overall score 0.5 士 0.4* 0.5 士 0.4* 0.8 ± 0.4* 
Values are presented as mean 土 standard deviations; *尸 value < 0.05; **尸 value < 0.01 (ANOVA). 
85 
. - • • 
• - . . . • 
• • • • 
• , . . ‘ . . 
- : . . 、 . • . . • . 
• . _• f , . - . 
• . . . . . .- : . . ‘ ‘ 
. . . . . . . . . . • � . V , • . 
7:.,.....:.〜,，”:.I,、：:':. V .. 
• 广...：• “ •：.； , r . : . . . . . ‘ . . 







 " . . .
 •
 >
 •
 ;
 :
 •
 • -
 :
 •
 •
 -
 • •
 -
 '
 •
 • 
- . 
